RxDoctor Payments Data

Matthew Eagleson, DO

Pain Medicine · Saginaw, MINPI 1295020048

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,879 of the $7,107 with a category attached, or 68.6%. Medtronic accounts for 71.3% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $3,858 and has fallen 86.6% since, to $517 in 2025.

$7,107in general payments, 2019–2025

Across 182 payments — averaging $39.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Nevro Corp.$729
  • AbbVie$392
  • Globus Medical$162
  • Vertiflex, Inc.$125
  • Abbott$114
  • plus $520 from 15 others

What the payments were for

  • Travel & lodging$2,22831%
  • Food & beverage$4,87969%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,107 in reported general payments places this provider in the 75th percentile of 139 pain medicine providers in Michigan.

See all pain medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$177,582
Medicare patients
258
Services billed
6,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl33$21,648
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen549$10,615
Buprenorphine45$10,118
Fentanyl48$9,446
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen131$4,161
Morphine Sulfate ErMorphine Sulfate127$3,421
Buprenorphine Hcl67$3,208
Gabapentin171$2,404
Tramadol Hcl ErTramadol Hcl31$1,624
Pregabalin91$1,428
Methadone Hcl45$1,082
Cyclobenzaprine Hcl25$962
Duloxetine Hcl35$868
Morphine Sulfate32$695
Hydrocodone-IbuprofenHydrocodone/Ibuprofen13$668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$38$21,64833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 139 pain medicine providers in Michigan.

Other pain medicine in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →